Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPARHT trial of dapagliflozin for renal protection in heart transplant recipients
NL-OMON51463Phase 3Not yet recruiting
- Sponsor
- Oslo University Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Chronic slope of estimated glomerular filtration rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON51463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51463.